Share on facebook
Share on twitter
Share on linkedin

August 15, 2015: BioAegis Therapeutics Presents to NIAID and BARDA Regarding Plasma Gelsolin and Its Role in Combatting Antimicrobial Resistance

NIAID Anticipates Funding Host-Based Approaches to Antimicrobial Resistance

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 15, 2015) BioAegis Therapeutics announces that it has met with representatives from The National Institute of Allergy and Infectious Diseases (NIAID) and The Biomedical Advanced Research Development Agency (BARDA) to discuss plasma gelsolin’s role in in combatting antibiotic resistance. The meeting was prompted by a recent National Action Plan sponsored by the White House to slow the emergence of resistant bacteria and prevent the spread of resistant infections. Plasma gelsolin offers a unique approach to solving this enormous threat to public health by using a host-based approach–empowering the body’s immune system to combat both bacterial and viral threats, especially where current therapies fail.